SABCS   |  December 15, 2019   Long-Term Follow-Up Supports Anastrozole Treatment to Prevent Breast Cancer Recurrence Five years of treatment with anastrozole safely and effectively prevented breast cancer recurrence in high-risk postmenopausal women at 10.9 years of follow-up. Read more   ADVERTISEMENT   Addition of S-1 to Endocrine Therapy Postoperatively Improves Survival in HR+, HER2- Breast Cancer Adjuvant therapy with S-1, an oral fluoropyrimidine-based drug, plus endocrine therapy postoperatively significantly increased invasive disease-free survival (IDFS) in patients with HR-positive, HER2-negative breast cancer. Read more